Plus Therapeutics Soars 14.21% on CNSide Launch

On August 5, 2025, Plus Therapeutics' stock surged by 14.21% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Plus Therapeutics has recently launched its CNSide Diagnostic Platform, a high-accuracy diagnostic tool for leptomeningeal metastases. This platform is designed to provide precise and reliable diagnostic results, which is crucial for the early detection and treatment of this condition. The launch of CNSide in Texas is a strategic move that aims to bring this advanced diagnostic tool to a broader market, potentially enhancing the company's market position and revenue streams.

The introduction of CNSide is expected to have a positive impact on Plus Therapeutics' stock performance. The diagnostic platform not only addresses a critical medical need but also positions the company as a leader in innovative diagnostic solutions. This development is likely to attract more investors and boost market confidence in the company's future prospects.